Application of low intensity laser radiation in extravasal infiltrates caused by cytostatics in children with acute leukemia.
Application of low intensity laser radiation in the field of infantile oncohematology has not been discussed in the available medical literature. The possible adverse effect of the physical factors on the main disease and the controversial character of their application prevent their being used in the treatment of these diseases. The aim of the present study was to assess the feasibility of using low intensity laser radiation (LILR) in treating extravasal infiltrates caused by cytostatics (vincristin, daunorubicin) administered in children with acute leukaemia (AL). We applied laser therapy in a group of children with AL in the stage of exacerbation. The children were undergoing chemotherapy with cytostatics. Immediately after formation of the extravasal infiltrates the constant leaders in the venous duct were removed and low intensity laser therapy with LMS "Prometheus" was administered. This apparatus is a semi-conducting soft laser in the infrared spectrum (890-910 nm wavelength, depth of penetration 25-30 mm) working in an impulse mode. We used minimal doses in the range of the anti-inflammatory enthrophic frequencies. We found that the extravasal infiltrates rapidly decreased the local inflammatory response and the pain was relieved. The strong anti-inflammatory effect can be accounted for by the nonspecific action of the LIRR on the tissues, which is manifested by better microcirculation, removal of toxic substances and stimulated regeneration capabilities of the cells. This study is an attempt to work successfully in this very delicate field of the contemporary medicine despite the abstention from using it before.
Goranova
V
V
Department of Physical Therapy and Rehabilitation, Higher Medical Institute, Plovdiv.
Marinckiev
M
M
Goranova
M
M
Sapunarova
K
K
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D006099:Granuloma / Q000139:chemically induced / Q000532:radiotherapy*; D006801:Humans; D007834:Lasers; D007938:Leukemia / Q000188:drug therapy*; D014750:Vincristine / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D003630:Daunorubicin